ORIC ORIC Pharmaceuticals, Inc.

QT27

Latest market price

9.24

+0.25+2.78%

Overview Short InterestFilings

ORICQT27ORIC Pharmaceuticals, Inc.·NASDAQ

Overview Short InterestFilings

9.24+2.78%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

TRAX-0.33%$45.08 NVAX-3.72%$10.08 NUVB-0.21%$4.76 KLRA-4.10%$12.86 REPL+1.27%$17.61 STOK-0.23%$26.29 QURE-1.86%$24.83 NTLA-5.74%$12.47

Snapshot

Index	—	P/E	—	EPS (ttm)	-1.35	Insider Own	18.42%	Shs Outstand	103.65M	Perf Week	-29.84%

Market Cap	957.75M	Forward P/E	—	EPS next Y	-1.67	Insider Trans	-0.66%	Shs Float	48.77M	Perf Month	-26.20%

Enterprise Value	695.75M	PEG	—	EPS next Q	-0.38			Short Float	31.62%	Perf Quarter	-12.83%

Income	-141.00M	P/S	—	EPS this Y	—			Short Ratio	10.40	Perf Half Y	-5.42%

Sales	0.00	P/B	2.51	EPS next Y	—	ROA	-34.68%	Short Interest	15.42M	Perf YTD	12.96%

Book/sh	3.68	P/C	3.61	EPS next 5Y	—	ROE	-35.35%	52W High	14.68 -37.06%	Perf Year	-28.54%

Cash/sh	2.56	P/FCF	—	EPS past 3/5Y	—	ROIC	-40.32%	52W Low	7.23 27.80%	Perf 3Y	54.00%

Dividend Est.	—	EV/EBITDA	—	Sales past 3/5Y	—	Gross Margin	0.00%	Volatility	14.53% 8.50%	Perf 5Y	-37.99%

Dividend TTM	—	EV/Sales	—	EPS Y/Y TTM	—	Oper. Margin	0.00%	ATR (14)	1.03	Perf 10Y	—

Dividend Ex-Date	—	Quick Ratio	13.19	Sales Y/Y TTM	—	Profit Margin	0.00%	RSI (14)	32.91	Recom	2.00

Dividend Gr. 3/5Y	—	Current Ratio	13.19	EPS Q/Q	19.15%	SMA20	-20.68%	Beta	1.17	Target Price	21.00

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	—	SMA50	-25.85%	Rel Volume	1.55	Prev Close	8.99

Employees	111	LT Debt/Eq	0.00	Earnings	Nov 12	SMA200	-17.05%	Avg Volume	1.58M	Price	9.24

IPO Date	Apr 24, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	-5.75% —	Net Debt/EBITDA	—	Volume	2,441,588	Change	2.78%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Oct-27-26	Reiterated	Wedbush	Outperform	$20 → $14
Oct-26-26	Reiterated	Stifel Nicolaus		$14 → $18
Oct-05-26	Initiated	Leerink	Outperform	$26
Sep-23-26	Initiated	BTIG	Buy	$26
Aug-10-26	Reiterated	HC Wainwright & Co.	Buy	$25 → $27
May-15-26	Reiterated	Goldman Sachs		$15
Feb-24-26	Reiterated	Oppenheimer	Outperform	$12 → $15
Feb-24-26	Reiterated	HC Wainwright & Co.	Buy	$23 → $25
Jan-07-26	Initiated	Piper Sandler	Overweight	$22
Dec-08-25	Reiterated	Wells Fargo	Overweight	$25

Latest News· Times ET

Oct-28-26

Oct-28-2601:58AM

BTIG Reiterates Buy on ORIC Pharmaceuticals, Maintains $26 Price TargetBenzinga

Oct-27-26

Oct-27-2604:11AM

Oric Pharmaceuticals (NASDAQ:ORIC) Stock Crosses Below 200-Day Moving Average – Should You Sell?defenseworld.net

Oct-23-26

Oct-23-2605:27PM

ORIC Pharmaceuticals, Inc. (ORIC) Discusses Enozertinib Phase Ib Data and Commercial Opportunity in EGFR Atypical Non-Small Cell Lung Cancer Transcriptseekingalpha.com

01:06PM

Oric Pharmaceuticals' Enozertinib Shows 88% Response Rate in EGFR Lung Cancer Studymarketbeat.com

03:15AM

ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trialglobenewswire.com

03:15AM

ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026globenewswire.com

Oct-21-26

Oct-21-2612:26AM

ORIC Stock In Focus As New Lung Cancer Trial Data Heads To ESMO 2026Yahoo

Oct-19-26

Oct-19-2608:00AM

ORIC® Pharmaceuticals to Host Conference Call & Webcast to Review Enozertinib Data Being Presented at ESMO Congress 2026globenewswire.com

Oct-14-26

Oct-14-2605:20AM

Meta To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga

Oct-08-26

Oct-08-2601:12PM

Does ORIC (ORIC) Using Off‑Balance‑Sheet Funding for ORIC‑259 Redefine Its R&D Risk Strategy?Yahoo

Oct-05-26

Oct-05-2604:01PM

ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Developmentglobenewswire.com

04:57AM

Leerink Partners Initiates Coverage On ORIC Pharmaceuticals with Outperform Rating, Announces Price Target of $26Benzinga

Oct-02-26

Oct-02-2604:30PM

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)globenewswire.com

Sep-23-26

Sep-23-2602:36AM

BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26Benzinga

Sep-16-26

Sep-16-2606:31AM

ORIC Pharmaceuticals, Inc. (ORIC) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcriptseekingalpha.com

Company

ORIC Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to discovering and advancing innovative treatments for cancer patients across the United States. The company's pipeline includes several key clinical-stage drug candidates. ORIC-533 is an oral small molecule designed to inhibit CD73, addressing resistance to both chemotherapy and immunotherapy. Another candidate, ORIC-944, is an allosteric inhibitor targeting the polycomb repressive complex 2, specifically for the treatment of prostate cancer. Furthermore, ORIC-114 is a brain-penetrant, orally administered, irreversible inhibitor crafted to precisely target epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), demonstrating high potency against exon 20 insertion mutations. Beyond these advanced programs, ORIC Pharmaceuticals is also cultivating multiple early-stage precision medicines aimed at other mechanisms of cancer resistance. The company has established partnerships, including a licensing and collaboration agreement with Voronoi Inc., and a licensing agreement with Mirati Therapeutics, Inc. ORIC Pharmaceuticals was founded in 2014 and maintains its headquarters in South San Francisco, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	0	0	0	0	—	—	—	—	—
Cost of Goods Sold Incl. D&A	0	1	1	1	—	—	—	—	—
Gross Profit	0	-1	-1	-1	—	—	—	—	—
Selling, General and Administrative Excl. Other	34	33	29	26	—	—	—	—	—
Research and Development	122	110	114	85	—	—	—	—	—
Other Operating Expense	0	-1	-1	-1	—	—	—	—	—
Operating Income	-157	-143	-143	-111	—	—	—	—	—
Interest Expense	0	0	0	0	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	16	14	15	10	—	—	—	—	—
Net Income Before Taxes	-141	-129	-128	-101	—	—	—	—	—
Income Taxes	0	0	0	0	—	—	—	—	—
Consolidated Net Income	-141	-129	-128	-101	—	—	—	—	—
Net Income From Continuing Operations	-141	-129	-128	-101	—	—	—	—	—
Net Income	-141	-129	-128	-101	—	—	—	—	—
EPS (Recurring)	-1.35	-1.47	-1.83	-1.96	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	-1.35	-1.47	-1.83	-1.96	—	—	—	—	—
EPS (Diluted)	-1.35	-1.47	-1.83	-1.96	—	—	—	—	—
EBITDA	-142	-128	-127	-100	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	108	88	70	51	—	—	—	—	—
Market Capitalization	998	720	565	469	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Piscitelli Dominic	Chief Financial Officer	Oct 20 '26	Option Exercise	4.36	14,000	61,040	83,828	Oct 21
Piscitelli Dominic	Chief Financial Officer	Oct 20 '26	Sale	13.53	14,000	189,391	69,828	Oct 21
Heyman Richard A.	Director	Oct 01 '26	Sale	12.91	6,700	86,524	38,300	Oct 02
Heyman Richard A.	Director	Oct 01 '26	Option Exercise	1.60	3,500	5,600	41,800	Oct 02
Piscitelli Dominic	Chief Financial Officer	Sep 28 '26	Option Exercise	4.36	13,400	58,424	83,228	Sep 29
Piscitelli Dominic	Chief Financial Officer	Sep 28 '26	Sale	13.53	13,400	181,258	69,828	Sep 29
Piscitelli Dominic	Chief Financial Officer	Sep 24 '26	Sale	13.50	600	8,103	69,828	Sep 25
Piscitelli Dominic	Chief Financial Officer	Sep 24 '26	Option Exercise	4.36	600	2,616	70,428	Sep 25
Piscitelli Dominic	Chief Financial Officer	Aug 26 '26	Option Exercise	4.89	77,000	376,720	146,828	Aug 28
Piscitelli Dominic	Chief Financial Officer	Aug 26 '26	Sale	13.69	77,000	1,053,814	69,828	Aug 28
Heyman Richard A.	Director	Jul 24 '26	Sale	12.02	13,100	157,462	38,300	Jul 28
Heyman Richard A.	Director	Jul 24 '26	Option Exercise	1.60	3,500	5,600	45,300	Jul 28
Heyman Richard A.	Director	Jul 06 '26	Sale	12.00	300	3,600	212,772	Jul 08
Piscitelli Dominic	Chief Financial Officer	Feb 24 '26	Sale	13.51	52,000	702,686	68,148	Feb 26
Piscitelli Dominic	Chief Financial Officer	Feb 24 '26	Option Exercise	4.36	52,000	226,720	120,148	Feb 26

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.